| Application | Recommended Dilution |
|---|---|
| FC | 1:50-1:200 |
CD46, also known as membrane cofactor protein, serves as a critical regulator of complement activation by acting as a cofactor for the serum protease factor I, which cleaves C3b and C4b deposited on host cell surfaces. This protective mechanism prevents autologous complement-mediated damage and has made CD46 a significant focus in immunology, infectious disease research, and cancer biology. Notably, CD46 also functions as a receptor for several pathogens, including measles virus and certain strains of adenovirus, while its expression patterns on tumor cells have drawn attention in oncology research.
This recombinant monoclonal antibody, clone 4E8, offers researchers the reproducibility and consistency that comes with sequence-defined production. Unlike traditional hybridoma-derived antibodies, recombinant technology ensures that every lot performs identically, eliminating the variability that can compromise longitudinal studies or multi-site collaborations. The human IgG1 isotype format provides predictable binding characteristics for downstream applications.
Validated for ELISA and flow cytometry, this antibody demonstrates clear utility for cell surface detection of CD46. Flow cytometry validation using HepG2 cells confirms robust detection of surface-expressed CD46, with recommended dilutions ranging from 1:50 to 1:200 providing flexibility to optimize signal-to-noise ratios across different experimental conditions. The validation data shows distinct separation between CD46-positive populations and isotype control, indicating specific target recognition on human hepatocellular carcinoma cells.
Supplied in a glycerol-based PBS buffer at pH 7.4 with Proclin 300 preservative, this affinity-purified antibody is well-suited for researchers investigating complement regulation, viral entry mechanisms, or CD46 expression in cancer models.
Email: support@cusabio.com
Distributors Worldwide